DarshanTalks Podcast

Send us Fan Mail  AI expert Dave Bulger, delves into the world of #AI, highlighting the distinction between AI and large language models (LLMs). He exposes the limitations of generative AI, raises concerns about copyright in content generation, and explores AI's potential impact across industries. Dave underscores that while LLMs can generate text, they lack true understanding. The conversati...

Send us Fan Mail  We explore the world of biohacking, with a particular focus on the emerging trend of "testosterone parties." These biohacking practices raise concerns regarding safety, efficacy, and misleading promotion, as many unapproved applications lack scientific support. It's worth noting that the FBI oversees biohacking, despite its primary purpose not being generalized res...

Send us Fan Mail  Mayya Tatsene has been issued a final debarment order by the FDA. The reason for the debarment stems from violating FDA regulations concerning clinical trials. Specifically, Tatsene failed to test on the appropriate number of subjects, thus compromising the integrity and reliability of the trial data. How to Avoid this Fate: To sidestep such consequences, individuals and organiza...

Send us Fan Mail  The FDA's Center for Tobacco Products (CTP) was created in 2009 to regulate tobacco products. Micah Berman worked at CTP from 2011-2012. He discusses the CTP's evolution in the past decade and shares insights from his recent article published in the New England Journal of Medicine. We discussed the following:  When was Micah a part of CTP? - 0:58 - 1:27  What was the vi...

Send us Fan Mail  Darshan Kulkarni emphasizes that companies considering #acquisitions must be ready for scrutiny from multiple agencies: FDA, FTC, DOJ, and OIG. FDA examines various aspects like manufacturing, clinical research, pharmacovigilance, advertising, and distribution. FTC now addresses advertising and antitrust concerns. DOJ concentrates on corporate compliance. Is your organization wel...

Send us Fan Mail  In this episode, the focus is on planning #FDA meetings and the significance of pre-IND meetings. We discuss how pre-IND meetings are crucial for identifying and addressing any roadblocks or gaps in the preclinical program before the actual filing. By doing so, potential delays or complications during the clinical trial phase can be mitigated. The discussion also includes insight...

Send us Fan Mail  Isaac Rodriguez-Chavez discusses the role and the significance of the Decentralized Clinical Trials guidance.  We discuss the following:  What are decentralized clinical trials? - 2:05- 4:25  What factors led to the rise of decentralized trials? – 4:26- 10:58  What is the role of decentralized clinical trials?- 10:59- 14:36  What is the process of FDA to develop a guidance?- 14:4...

Send us Fan Mail  Istvan Fekete and Darshan Kulkarni discuss the 7 types of clinical trial agreements (CTAs). CTAs Explored Include:   Industry-Sponsored Trials,  Phase Four and Post-Market Studies,  Registry Studies,  Federally Funded Studies,  Drug and Device Studies,  Consortium Studies,  Investigator-Initiated Studies:  We discuss the potential risks of seeding trials, and the need for both sp...